India Pharma - Growth Trajectory In IPM Moderates In October: Motilal Oswal
The Indian pharma market exhibited a growth of 7% YoY in October 2022 versus a growth of 13%/5% YoY in September 2022/Oct-21.
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
The Indian pharma market exhibited a growth of 7% YoY in October 2022 versus a growth of 13%/5% YoY in September 2022/Oct-21. Despite a lower base, growth YoY was subdued in Oct-22.
Cardiac/dermatology/respiratory/gynecology was the major growth drivers for the IPM, up 9.8%/11.8%/10.6%/16.4% YoY.
YoY growth in the IPM for Oct-22 was impacted by a stable growth in the antiInfectives segment and moderate growth of ~5.5% in gastrointestinal and the diabetes segment.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.